Influence of the dopaminergic system on motor learning

• Conditions: G20; Parkinson disease

• Registration Number: DRKS00026167
• Lead Sponsor: Klinik für Neurologie, Uniklinik Leipzig

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-24
• Study Completion: 2023-06-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age between 40 and 75. Signing of informed consent. Only subjects with previous nuclear medicine examination: V.a. a parkinsonian syndrome (which led to referral to nuclear medicine for FP-CIT SPECT examination).

Exclusion Criteria

Non-consent or inability of the subject to consent to study participation; pre-existing high-dose symptomatic dopaminergic therapy (> 600 mg levodopa equivalent dose); relevant postural disorder (regular falls, propensity to fall in the so-called pull test); alcohol/drug abuse (current or history); depression (BDI > 19 points); acute psychotic symptomatology; severe previous internal disease (e.g., heart failure. e.g., heart failure) or orthopedic/rheumatologic pre-existing conditions that interfere with expenditure performance; inability to perform the experimental tasks; pregnancy; relevant daytime sleepiness (ESS >12), relevant cognitive impairment (MOCA score < 18).

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Extent of motor learning in patients with Parkinson's disease compared to healthy controls.

Secondary Outcome Measures

Name	Time	Method
Extent of learning success dependent on dopaminergic deficit in DaTScan in patients with parkinson disease.